<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Mometasone (topical): Drug information</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Mometasone (topical): Drug information</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="drugTitle">Mometasone (topical): Drug information</div><div class="clear"></div><div id="topicText">(For additional information <a class="drug drug_patient" data-topicid="12258" href="/d/html/12258.html" rel="external">see "Mometasone (topical): Patient drug information"</a> and <a class="drug drug_pediatric" data-topicid="16023" href="/d/html/16023.html" rel="external">see "Mometasone (topical): Pediatric drug information"</a>)<br/><br/>For abbreviations, symbols, and age group definitions used in Lexicomp (<a class="graphic graphic_table" href="/d/html/57469.html" rel="external">show table</a>)<div class="visuallyHidden drugH1Div" id="formulinkBodyPlaceholder"><span class="drugH1"></span></div>
<div class="list ubnlist drugH1Div drugBrandNames" id="F8775141"><span class="drugH1">Brand Names: US</span>
<ul>
<li>Elocon [DSC]</li></ul></div>
<div class="list canbnlist drugH1Div drugBrandNames" id="F52869254"><span class="drugH1">Brand Names: Canada</span>
<ul>
<li>Elocom;</li>
<li>TARO-Mometasone;</li>
<li>TEVA-Mometasone</li></ul></div>
<div class="ex_sect_xr thclist drugH1Div drugBrandNames" id="F8775150"><span class="drugH1">Pharmacologic Category</span>
<ul>
<li>
                        Corticosteroid, Topical</li></ul></div>
<div class="block doa drugH1Div" id="F8775297"><span class="drugH1">Dosing: Adult</span>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="7fcdd7c2-fcea-459c-b474-e68d6e2cb01d">Corticosteroid-responsive dermatoses</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Corticosteroid-responsive dermatoses:</b>
<b>Topical:</b> Apply sparingly, do not use occlusive dressings. Therapy should be discontinued when control is achieved; consider reassessment of diagnosis if no improvement is seen within 2 weeks.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Cream, ointment:</i> Apply a thin film to affected area once daily.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Lotion, solution:</i> Apply a few drops to affected area once daily.</p></div>
</div>
</div>
<div class="block dora drugH1Div" id="F50991499"><span class="drugH1">Dosing: Kidney Impairment: Adult</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer’s labeling.</p></div>
<div class="block doha drugH1Div" id="F50988863"><span class="drugH1">Dosing: Hepatic Impairment: Adult</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer’s labeling.</p></div>
<div class="block doe drugH1Div" id="F8775298"><span class="drugH1">Dosing: Older Adult</span>
<p style="text-indent:0em;display:inline">Refer to adult dosing. Use with caution as elderly patients may be more susceptible to systemic effects.</p></div>
<div class="block dop drugH1Div" id="F8775296"><span class="drugH1">Dosing: Pediatric</span><p>(For additional information <a class="drug drug_pediatric" data-topicid="16023" href="/d/html/16023.html" rel="external">see "Mometasone (topical): Pediatric drug information"</a>)</p>
<p style="text-indent:0em;display:inline">
<b>Note:</b> Discontinue therapy when control is achieved; reassess diagnosis if no improvement is seen in 2 weeks</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="7fcdd7c2-fcea-459c-b474-e68d6e2cb01d">Corticosteroid-responsive dermatoses</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Corticosteroid-responsive dermatoses:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Cream, ointment:</i> Children ≥2 years and Adolescents: Topical: Apply a thin film to affected area once daily; do not use in pediatric patients for &gt;3 weeks</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Lotion, solution:</i> Children ≥12 years and Adolescents: Topical: Apply a few drops to affected area once daily; massage lightly into skin</p></div>
</div>
</div>
<div class="block dorp drugH1Div" id="F51130328"><span class="drugH1">Dosing: Kidney Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer’s labeling.</p></div>
<div class="block dohp drugH1Div" id="F51130329"><span class="drugH1">Dosing: Hepatic Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer’s labeling.</p></div>
<div class="block adr drugH1Div" id="F8775239"><span class="drugH1">Adverse Reactions</span>
<p style="text-indent:0em;display:inline">The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified.</p>
<p style="text-indent:0em;">1% to 10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Central nervous system: Paresthesia (lotion, infants &amp; children: ≤3%, cream, children: 1%)</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Dyschromia (loss of normal skin markings: ≤6%), taut and shiny skin (≤6%), folliculitis (lotion: 3%; cream, children: &lt;1%), telangiectasia (≤3%), dermatologic disorders (2%), bacterial skin infection (infants &amp; children: ≤2%), epidermal thinning (≤2%)</p>
<p style="text-indent:-2em;margin-left:4em;">Endocrine &amp; metabolic: Decreased cortisol (infants &amp; children: lotion: ≤6%, cream and ointment: ≤2%), endocrine disease (lotion: 2%)</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Xerostomia (infants &amp; children: 2%)</p>
<p style="text-indent:-2em;margin-left:4em;">Hematologic &amp; oncologic: Bruise (1%)</p>
<p style="text-indent:-2em;margin-left:4em;">Local: Application site burning (2%), application site pruritus (≤2%)</p>
<p style="text-indent:-2em;margin-left:2em;">Frequency not defined:</p>
<p style="text-indent:-2em;margin-left:4em;">Central nervous system: Tingling of skin</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Acne rosacea, furunculosis, skin atrophy, stinging of the skin (application site)</p>
<p style="text-indent:-2em;margin-left:2em;">&lt;1%, postmarketing, and/or case reports: Acneiform eruption, cataract, cutaneous candidiasis, glaucoma, skin depigmentation</p></div>
<div class="block coi drugH1Div" id="F8775236"><span class="drugH1">Contraindications</span>
<p style="text-indent:-2em;margin-left:2em;">Hypersensitivity to mometasone furoate or any component of the formulation.</p>
<p style="text-indent:-2em;margin-left:2em;">
<i>Canadian labeling:</i> Additional contraindications (not in US labeling): viral (eg, herpes or varicella) lesions of the skin, fungal or bacterial skin infections, parasitic infections, skin manifestations relating to tuberculosis or syphilis, eruptions following vaccinations, acne vulgaris, rosacea, pruritus without inflammation; ophthalmic use; use with occlusive dressings</p></div>
<div class="block war drugH1Div" id="F8775237"><span class="drugH1">Warnings/Precautions</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Concerns related to adverse effects:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Adrenal suppression: May cause hypercortisolism or suppression of hypothalamic-pituitary-adrenal (HPA) axis, particularly in younger children or in patients receiving high doses for prolonged periods. HPA axis suppression may lead to adrenal crisis.</p>
<p style="text-indent:-2em;margin-left:4em;">•Contact dermatitis: Allergic contact dermatitis can occur and is usually diagnosed by failure to heal rather than clinical exacerbation; discontinue use if irritation occurs and treat appropriately.</p>
<p style="text-indent:-2em;margin-left:4em;">• Immunosuppression: Prolonged use may result in fungal or bacterial superinfection; discontinue if dermatological infection persists despite appropriate antimicrobial therapy.</p>
<p style="text-indent:-2em;margin-left:4em;">• Ocular effects: Topical corticosteroids, including mometasone, may increase the risk of posterior subcapsular cataracts and glaucoma. Monitor for ocular changes. Avoid contact with eyes.</p>
<p style="text-indent:-2em;margin-left:4em;">• Systemic effects: Topical corticosteroids may be absorbed percutaneously. Absorption of topical corticosteroids may cause manifestations of Cushing's syndrome, hyperglycemia, or glycosuria. Absorption is increased by the use of occlusive dressings, application to denuded skin, or application to large surface areas.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Special populations:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Older adult: Because of the risk of adverse effects associated with systemic absorption, topical corticosteroids should be used cautiously in the elderly in the smallest possible effective dose for the shortest duration.</p>
<p style="text-indent:-2em;margin-left:4em;">• Pediatric: Not for treatment of diaper dermatitis. Children may absorb proportionally larger amounts after topical application and may be more prone to systemic effects. HPA axis suppression, intracranial hypertension, and Cushing syndrome have been reported in children receiving topical corticosteroids. Prolonged use may affect growth velocity; growth should be routinely monitored in pediatric patients.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Dosage form specific issues:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Appropriate use: Avoid use of topical preparations with occlusive dressings or on weeping or exudative lesions.</p></div>
<div class="block add-pediatric-warn-info drugH1Div" id="F52878749"><span class="drugH1">Warnings: Additional Pediatric Considerations</span>
<p style="text-indent:0em;display:inline">The extent of percutaneous absorption is dependent on several factors, including epidermal integrity (intact vs abraded skin), formulation, age of the patient, prolonged duration of use, and the use of occlusive dressings. Percutaneous absorption of topical steroids is increased in neonates (especially preterm neonates), infants, and young children. Infants and small children may be more susceptible to HPA axis suppression, intracranial hypertension, Cushing syndrome, or other systemic toxicities due to larger skin surface area to body mass ratio.</p>
<p style="text-indent:0em;margin-top:2em;">Open-label safety studies conducted in infants and children 6 to 23 months of age with atopic dermatitis demonstrated a high incidence of adrenal suppression when topical mometasone furoate products were applied once daily for approximately 3 weeks over a mean BSA of ~40%. Of the patients with normal baseline adrenal function, adrenal suppression occurred in 16% of patients using the cream, 27% of patients using the ointment, and 29% of patients using the lotion/solution. Follow-up testing 2 to 4 weeks after discontinuation of therapy demonstrated suppressed HPA axis function in 1 of 5 patients who used the cream, 3 of 8 patients who used the ointment, and 1 of 8 patients who used the lotion/solution. Due to a higher BSA to weight ratio, pediatric patients are at a greater risk of HPA axis suppression and Cushing syndrome compared to adults. Application of topical steroids over &gt;20% of BSA in pediatric patients increases risk of HPA axis suppression.</p>
<p style="text-indent:0em;margin-top:2em;">Some dosage forms may contain propylene glycol; in neonates large amounts of propylene glycol delivered orally, intravenously (eg, &gt;3,000 mg/day), or topically have been associated with potentially fatal toxicities which can include metabolic acidosis, seizures, renal failure, and CNS depression; toxicities have also been reported in children and adults including hyperosmolality, lactic acidosis, seizures, and respiratory depression; use caution (AAP 1997; Shehab 2009).</p></div>
<div class="block foc drugH1Div" id="F8775347"><span class="drugH1">Dosage Forms: US</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.  [DSC] = Discontinued product</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Cream, External, as furoate: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Elocon: 0.1% (50 g [DSC]) [contains soybean lecithin]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 0.1% (15 g, 45 g)</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Ointment, External, as furoate: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 0.1% (15 g, 45 g)</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution, External, as furoate: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 0.1% (30 mL, 60 mL)</p></div>
<div class="block geq drugH1Div" id="F8775144"><span class="drugH1">Generic Equivalent Available: US</span>
<p style="text-indent:0em;display:inline">Yes</p></div>
<div class="block fee drugH1Div" id="F8775349"><span class="drugH1">Pricing: US</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Cream</b> (Mometasone Furoate External)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">0.1% (per gram): $1.94</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Ointment</b> (Mometasone Furoate External)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">0.1% (per gram): $1.23 - $1.73</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Solution</b> (Mometasone Furoate External)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">0.1% (per mL): $0.97 - $1.00</p>
<p style="text-indent:0em;">
<b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>
<div class="block dinfoc drugH1Div" id="F52869255"><span class="drugH1">Dosage Forms: Canada</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Cream, External, as furoate: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Elocom: 0.1% (15 g, 50 g) [contains soybean lecithin]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 0.1% (15 g, 50 g)</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Lotion, External: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Elocom: 0.1% (75 mL) [contains isopropyl alcohol, propylene glycol]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 0.1% (30 mL, 60 mL, 75 mL)</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Ointment, External, as furoate: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Elocom: 0.1% (50 g) [contains propylene glycol monostearate]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 0.1% (15 g, 50 g)</p></div>
<div class="block adm drugH1Div" id="F8775300"><span class="drugH1">Administration: Adult</span>
<p style="text-indent:0em;display:inline">Apply sparingly. Avoid mucous membranes; manufacturer labeling recommends avoiding application to the eyes, face, underarms, and groin (including diaper area). Do not wrap, cover, or bandage affected area.</p>
<p style="text-indent:-2em;margin-left:2em;">Cream, ointment: Apply thin film to affected area.</p>
<p style="text-indent:-2em;margin-left:2em;">Lotion, solution: Apply a few drops to affected area and massage lightly until medication disappears.</p></div>
<div class="block admp drugH1Div" id="F52614378"><span class="drugH1">Administration: Pediatric</span>
<p style="text-indent:-2em;margin-left:2em;">Topical: Apply sparingly; avoid contact with eyes. Do not apply to face, underarms, or groin. Do not wrap or bandage or use occlusive dressings to affected area, unless directed by the physician. Do not use for treatment of diaper dermatitis or in diaper area. Wash hands after application.</p>
<p style="text-indent:-2em;margin-left:2em;">Cream, ointment: Apply thin film to affected area.</p>
<p style="text-indent:-2em;margin-left:2em;">Lotion, solution: Hold tip of bottle close to affected area and gently squeeze bottle to apply a few drops to affected area.</p></div>
<div class="block use drugH1Div" id="F8775230"><span class="drugH1">Use: Labeled Indications</span>
<p style="text-indent:0em;display:inline">
<b>Corticosteroid-responsive dermatoses:</b> Relief of the inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses (medium potency topical corticosteroid)</p></div>
<div class="block mst drugH1Div" id="F8775128"><span class="drugH1">Medication Safety Issues</span>
<div class="collapsible">
<span class="collapsible-title">Sound-alike/look-alike issues:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">Elocon lotion may be confused with ophthalmic solutions. Manufacturer's labeling emphasizes the product is <b>NOT</b> for use in the eyes.</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Pediatric patients: High-risk medication:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">KIDs List: Medium, high, and very high potency topical corticosteroids, when used in neonates and infants &lt;1 year of age for diaper dermatitis, are identified on the Key Potentially Inappropriate Drugs in Pediatrics (KIDs) list; use should be avoided due to risk of adrenal suppression; systemic absorption is higher in pediatric patients than adults (strong recommendation; low quality of evidence) (PPA [Meyers 2020]).</p></div>
</div>
</div>
<div class="block cyt drugH1Div" id="F8775244"><span class="drugH1">Metabolism/Transport Effects</span>
<p style="text-indent:0em;display:inline">
<b>Substrate</b> of CYP3A4 (minor); <b>Note:</b> Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential</p></div>
<div class="block dri drugH1Div" id="F8775245"><span class="drugH1">Drug Interactions</span><br/><br/><div class="clear"></div><p xmlns=""></p><div class="inner" xmlns=""><p style="text-indent:0em;display:inline"><b>Note</b>: Interacting drugs may <b>not be individually listed below</b> if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed).  For a complete list of drug interactions by individual drug name and detailed management recommendations, use the Lexicomp drug interactions program by clicking on the “Launch drug interactions program” link above.</p><p xmlns=""></p></div>
<p style="text-indent:-2em;margin-left:2em;">CYP3A4 Inhibitors (Strong): May increase the serum concentration of Mometasone (Topical).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Nirmatrelvir and Ritonavir: May increase the serum concentration of Corticosteroids (Topical).<i> Risk C: Monitor therapy</i></p></div>
<div class="block rep_considerations drugH1Div" id="F56154087"><span class="drugH1">Reproductive Considerations</span>
<p style="text-indent:0em;display:inline">Topical corticosteroids may be used for the treatment of corticosteroid-responsive dermatosis, such as atopic dermatitis, in patients planning a pregnancy (Vestergaard 2019).</p></div>
<div class="block pri drugH1Div" id="F8775232"><span class="drugH1">Pregnancy Considerations</span>
<p style="text-indent:0em;display:inline">Systemic bioavailability of topical corticosteroids is variable (integrity of skin, use of occlusion, etc) and may be further influenced by trimester of pregnancy (Chi 2017). In general, the use of topical corticosteroids is not associated with a significant risk of adverse pregnancy outcomes; however, there may be an increased risk of low-birth-weight infants following maternal use of potent or very potent topical products, especially in high doses, although this risk is likely to be low (Andersson 2021; Chi 2015; Chi 2017).</p>
<p style="text-indent:0em;margin-top:2em;">When first-line treatments, such as emollients, are insufficient, topical corticosteroids may be used for the treatment of atopic dermatitis in pregnant patients (Vestergaard 2019). Topical corticosteroids are classified by potency; the medication and formulation (eg, cream, gel, salt form) contribute to the potency classification (Oakley 2021; Stacey 2021; Tadicherla 2009). In general, use of the least potent product in limited amounts is recommended during pregnancy. Mild to moderate potency corticosteroids are preferred; potent to very potent topical corticosteroids should only be used as alternative therapy in limited amounts under obstetrical care. Pregnant patients should avoid application of topical corticosteroids to areas with high percutaneous absorption (eg, armpit, skin folds, vulva) (Chi 2017), and caution should be used when applying to areas prone to striae formation (eg, abdomen, breast, thighs) (Vestergaard 2019).</p></div>
<div class="block brc drugH1Div" id="F8775235"><span class="drugH1">Breastfeeding Considerations</span>
<p style="text-indent:-2em;margin-left:2em;">It is not known if sufficient quantities of mometasone are absorbed following topical administration to produce detectable amounts in breast milk; however, systemic corticosteroids are present in breast milk.</p>
<p style="text-indent:-2em;margin-left:2em;">Although the manufacturer recommends that caution be used, topical corticosteroids are generally considered acceptable for use in patients who are breastfeeding (Butler 2014; WHO 2002).</p>
<p style="text-indent:-2em;margin-left:2em;">Avoid application of topical corticosteroids to the nipple and areola area until breastfeeding ceases; hypertension was noted in a breastfed infant when a high-potency topical corticosteroid was applied to the nipple (AAD-NPF [Elmets 2021]; Butler 2014; Leachman 2006). If needed, apply topical corticosteroids immediately after breastfeeding and then clean nipples prior to the next feeding (Vestergaard 2019).</p></div>
<div class="block mop drugH1Div" id="F51471168"><span class="drugH1">Monitoring Parameters</span>
<p style="text-indent:0em;display:inline">Adrenal suppression with extensive/prolonged use (ACTH stimulation test, morning plasma cortisol test, urinary free cortisol test); response to treatment; ocular changes</p></div>
<div class="block pha drugH1Div" id="F8775251"><span class="drugH1">Mechanism of Action</span>
<p style="text-indent:0em;display:inline">Topical corticosteroids have anti-inflammatory, antipruritic, and vasoconstrictive properties. May depress the formation, release, and activity of endogenous chemical mediators of inflammation (kinins, histamine, liposomal enzymes, prostaglandins) through the induction of phospholipase A<sub>2</sub> inhibitory proteins (lipocortins) and sequential inhibition of the release of arachidonic acid. Mometasone has intermediate range potency.</p></div>
<div class="block phk drugH1Div" id="F8775253"><span class="drugH1">Pharmacokinetics (Adult Data Unless Noted)</span>
<p style="text-indent:0em;display:inline">Absorption: Cream: 0.4% (increased by inflammation); Lotion, ointment, solution: 0.7% (increased by inflammation)</p></div>
<div class="list fbnlist drugH1Div drugBrandNames" id="F10961989"><span class="drugH1">Brand Names: International</span><div class="ibn-search drugBrandNames"></div>
<div class="collapsible-indication brand-names-accordion drugBrandNames"><span class="collapsible-indication-title">International Brand Names by Country</span><div class="collapsible-indication-wrap-frame drugBrandNames"><div class="collapsible-indication-wrap drugBrandNames">For country code abbreviations (<a class="graphic graphic_table" href="/d/html/116421.html" rel="external">show table</a>)<br xmlns=""/><br/><ul>
<li>
<span class="countryCode">(AE)</span> <span class="country">United Arab Emirates</span><span class="countrySeparator">: </span><span class="drugName">Elica | Elocom | Glenmate | Metaz | Mometamed | Xemaderm | Zynovate</span>;</li>
<li>
<span class="countryCode">(AR)</span> <span class="country">Argentina</span><span class="countrySeparator">: </span><span class="drugName">Derimod | Elocon | Metason | Momefarm | Momeplus | Mometax | Novasone | Suavicort</span>;</li>
<li>
<span class="countryCode">(AT)</span> <span class="country">Austria</span><span class="countrySeparator">: </span><span class="drugName">Elocon | Momecutan | Mometason Arcana | Monovo</span>;</li>
<li>
<span class="countryCode">(AU)</span> <span class="country">Australia</span><span class="countrySeparator">: </span><span class="drugName">Elocon | Momasone | Novasone | Zatamil</span>;</li>
<li>
<span class="countryCode">(BD)</span> <span class="country">Bangladesh</span><span class="countrySeparator">: </span><span class="drugName">Elocan | Meloderm | Momeson | Mometa | Soneta</span>;</li>
<li>
<span class="countryCode">(BE)</span> <span class="country">Belgium</span><span class="countrySeparator">: </span><span class="drugName">Elocom</span>;</li>
<li>
<span class="countryCode">(BG)</span> <span class="country">Bulgaria</span><span class="countrySeparator">: </span><span class="drugName">Elocom | Mometasone abr</span>;</li>
<li>
<span class="countryCode">(BR)</span> <span class="country">Brazil</span><span class="countrySeparator">: </span><span class="drugName">Cutisone | Dermotil | Elocom | Furoato de mometasona | M lix | Resgat | Topison | Topliv</span>;</li>
<li>
<span class="countryCode">(CH)</span> <span class="country">Switzerland</span><span class="countrySeparator">: </span><span class="drugName">Elocom</span>;</li>
<li>
<span class="countryCode">(CI)</span> <span class="country">Côte d'Ivoire</span><span class="countrySeparator">: </span><span class="drugName">Elica</span>;</li>
<li>
<span class="countryCode">(CL)</span> <span class="country">Chile</span><span class="countrySeparator">: </span><span class="drugName">Dermaten | Dermenet | Dermosona | Elocom | Ermil | Euroderm | Flogocort | Lisoder | Momederm | Momelab | Sanazona | Suavicort</span>;</li>
<li>
<span class="countryCode">(CN)</span> <span class="country">China</span><span class="countrySeparator">: </span><span class="drugName">Ai luo song | Dian hong su qi | Eloson</span>;</li>
<li>
<span class="countryCode">(CO)</span> <span class="country">Colombia</span><span class="countrySeparator">: </span><span class="drugName">Bicalm | Dermacortine | Dermasone | Elocom | Flazcort | Furafar | Furm | Furoato de mometasona | Furoderm | Leaxin | Lenicort | Losalen | Mizor | Mometasona | Mometasona Furoato | Monovel</span>;</li>
<li>
<span class="countryCode">(CZ)</span> <span class="country">Czech Republic</span><span class="countrySeparator">: </span><span class="drugName">Elocom | Ovixan</span>;</li>
<li>
<span class="countryCode">(DE)</span> <span class="country">Germany</span><span class="countrySeparator">: </span><span class="drugName">Ecural | Elocom | Elocon | Momecutan | Momegalen | Mometahexal derm | Mometason glenmark | Mometop | Monovo</span>;</li>
<li>
<span class="countryCode">(DK)</span> <span class="country">Denmark</span><span class="countrySeparator">: </span><span class="drugName">Ovison</span>;</li>
<li>
<span class="countryCode">(DO)</span> <span class="country">Dominican Republic</span><span class="countrySeparator">: </span><span class="drugName">Aguanace | Cortiplus | Derma c | Dermacortine | Elocom | Elomet | Furaderm | Furomet | Marabea | Momate | Momederm | Momet | Mometasona | Mometasona if | Mometasona MK | Momevic | Regener | Votek</span>;</li>
<li>
<span class="countryCode">(EC)</span> <span class="country">Ecuador</span><span class="countrySeparator">: </span><span class="drugName">Dermacortine | Dermosona | Elomet | Flogocort | Furoato de mometasona | Momed | Mometasona | Mopac | Septopic</span>;</li>
<li>
<span class="countryCode">(EE)</span> <span class="country">Estonia</span><span class="countrySeparator">: </span><span class="drugName">Elocom | Elocon</span>;</li>
<li>
<span class="countryCode">(EG)</span> <span class="country">Egypt</span><span class="countrySeparator">: </span><span class="drugName">Allerzone | Borgasone | Elecortin | Elocon | Elocortin | Gridamom | Metasone | Metaz | Momsone | Wellmetazone</span>;</li>
<li>
<span class="countryCode">(ES)</span> <span class="country">Spain</span><span class="countrySeparator">: </span><span class="drugName">Elica | Elocom | Mometasona kern | Mometasona mede | Mometasona Tarbis | Mometasona viso farmaceutica</span>;</li>
<li>
<span class="countryCode">(ET)</span> <span class="country">Ethiopia</span><span class="countrySeparator">: </span><span class="drugName">Elica | Elna | Elocom | Melomet | Mometamed | Mometasone</span>;</li>
<li>
<span class="countryCode">(FI)</span> <span class="country">Finland</span><span class="countrySeparator">: </span><span class="drugName">Demoson | Elocon | Mommox | Ovixan</span>;</li>
<li>
<span class="countryCode">(GB)</span> <span class="country">United Kingdom</span><span class="countrySeparator">: </span><span class="drugName">Elocon | Mometasone | Mometasone teva</span>;</li>
<li>
<span class="countryCode">(GR)</span> <span class="country">Greece</span><span class="countrySeparator">: </span><span class="drugName">Bioelementa | Elocon | F din | Fremomet | Logren | Makiren | Mofur | Momecort | Mometasone target | Mometasone/help | Yperod</span>;</li>
<li>
<span class="countryCode">(HK)</span> <span class="country">Hong Kong</span><span class="countrySeparator">: </span><span class="drugName">Aliamet | Aplomet | Axcel mometasone | Elisone | Eloderm | Elomet | Elosone | Kolmar mometasone | Mle mometasone furoate | Netasone | Ravelia | Synlomed | Topcort | Vizomet | Zatamil</span>;</li>
<li>
<span class="countryCode">(HR)</span> <span class="country">Croatia</span><span class="countrySeparator">: </span><span class="drugName">Elocom</span>;</li>
<li>
<span class="countryCode">(HU)</span> <span class="country">Hungary</span><span class="countrySeparator">: </span><span class="drugName">Atozon | Azocutan | Elocom | Mofuder | Momegen | Mometasone mediner</span>;</li>
<li>
<span class="countryCode">(ID)</span> <span class="country">Indonesia</span><span class="countrySeparator">: </span><span class="drugName">Dermovel | Elocon | Elomep | Elomox | Eloskin | Elox | Ikaflam | Intercon | Mefurosan | Melocon | Mesone | Metagra | Mofacort | Mofulex | Mometasone | Motaderm | Moteson</span>;</li>
<li>
<span class="countryCode">(IE)</span> <span class="country">Ireland</span><span class="countrySeparator">: </span><span class="drugName">Elocon</span>;</li>
<li>
<span class="countryCode">(IL)</span> <span class="country">Israel</span><span class="countrySeparator">: </span><span class="drugName">Elocom</span>;</li>
<li>
<span class="countryCode">(IN)</span> <span class="country">India</span><span class="countrySeparator">: </span><span class="drugName">Azokid | Belmoz | Corticom | Cortimom | Cortina | Cratisone | Cricmone | Cutizone | Dermanex | Dermet | Dermiat | Eczisone | Elocon | Elosone | Emcort | Etaze | Ethimom | Ezimet | Ezoma | Ezosone | Femcort | Fumon | Hhsone | Medsone | Mesotop | Metacon | Metacort | Metacortil | Metasafe | Metasone | Metlar | Metos | Mezo | Mfsone | Midsone | Mkroma | Mmcod | Mms | Mofu | Momactin | Momate | Momax | Momben | Momecon | Momecort | Momenta | Momentox | Momesone | Momisoft | Momivate | Momocort | Momoz | Momsafe | Momstar | Momtas | Momtent | Momtop | Mone | Monosone | Mosone | Mova | Mscort | Mson | Msone | Mtaz | Mts | Mysone | Mytolic | Potenster | Qutimore | Sensicort | Steromom | Topcort | Ucecort | Vimet</span>;</li>
<li>
<span class="countryCode">(IQ)</span> <span class="country">Iraq</span><span class="countrySeparator">: </span><span class="drugName">Elika derm | Metason | Metazone</span>;</li>
<li>
<span class="countryCode">(IT)</span> <span class="country">Italy</span><span class="countrySeparator">: </span><span class="drugName">Altosone | Elocom | Elocon | Frondava | Mometasone sandoz | Mundoson | Ovison | Ovixan</span>;</li>
<li>
<span class="countryCode">(JO)</span> <span class="country">Jordan</span><span class="countrySeparator">: </span><span class="drugName">Elica | Elisone | Elna | Elocom | Mesone | Metaz | Xemaderm | Zynovate</span>;</li>
<li>
<span class="countryCode">(JP)</span> <span class="country">Japan</span><span class="countrySeparator">: </span><span class="drugName">Fulmeta | Mometasone furoate Iwaki</span>;</li>
<li>
<span class="countryCode">(KE)</span> <span class="country">Kenya</span><span class="countrySeparator">: </span><span class="drugName">Elica | Elocom | Momate | Momecort | Momson | Momtas | Motesone | Topcort</span>;</li>
<li>
<span class="countryCode">(KR)</span> <span class="country">Korea, Republic of</span><span class="countrySeparator">: </span><span class="drugName">Camilia | Cleantisone | Cumotasone | Curederm | Dermetasone | Dermisone | Dermotasone | Dermotasone mle | Eftasone | Elocom | Furetasone | Genuone mometasone | Hlb mometasone | Inpra | Inpura | J momeson | K zerotasone | Meisone | Methasone | Momecare | Momecot | Momecrin | Momederm | Moment | Momenta | Momentasone | Momeron | Momeskin | Momesol | Momeson | Momesone | Mometan | Mometasone | Moratason | Moricort | Motasone | Pieltason | Pltasone | Promon | Ravelia | Sg momezone | Terison | Terisone</span>;</li>
<li>
<span class="countryCode">(KW)</span> <span class="country">Kuwait</span><span class="countrySeparator">: </span><span class="drugName">Elica | Elocom | Metaz | Zynovate</span>;</li>
<li>
<span class="countryCode">(LB)</span> <span class="country">Lebanon</span><span class="countrySeparator">: </span><span class="drugName">Elecortin | Elica | Elisone | Elocom | Konex | Mometamed | Xemaderm | Zynovate</span>;</li>
<li>
<span class="countryCode">(LT)</span> <span class="country">Lithuania</span><span class="countrySeparator">: </span><span class="drugName">Belloseta | Elocom</span>;</li>
<li>
<span class="countryCode">(LU)</span> <span class="country">Luxembourg</span><span class="countrySeparator">: </span><span class="drugName">Elocom</span>;</li>
<li>
<span class="countryCode">(LV)</span> <span class="country">Latvia</span><span class="countrySeparator">: </span><span class="drugName">Belloseta | Elocom | Elocon</span>;</li>
<li>
<span class="countryCode">(MX)</span> <span class="country">Mexico</span><span class="countrySeparator">: </span><span class="drugName">Elica | Elomet | Medamestroid | Metactiv | Mometasona | Supridier | Yaguinor</span>;</li>
<li>
<span class="countryCode">(MY)</span> <span class="country">Malaysia</span><span class="countrySeparator">: </span><span class="drugName">Alesone | Axcel mometasone | Bitvio | Elomet | Elosone | Mefurosan | Melomet | Metasone | Momate | Vizomet</span>;</li>
<li>
<span class="countryCode">(NG)</span> <span class="country">Nigeria</span><span class="countrySeparator">: </span><span class="drugName">Fumecon</span>;</li>
<li>
<span class="countryCode">(NL)</span> <span class="country">Netherlands</span><span class="countrySeparator">: </span><span class="drugName">Elocon | Mometason Furoaat A | Mometasonfuroaat bmodesto | Mometasonfuroaat eureco pharma | Mometasonfuroaat fisher | Mometasonfuroaat Glenmark | Mometasonfuroaat teva | Mometasonfuroaat Vet Mylan</span>;</li>
<li>
<span class="countryCode">(NO)</span> <span class="country">Norway</span><span class="countrySeparator">: </span><span class="drugName">Elocom | Elocon | Momecutan | Mometason glenmark | Ovixan</span>;</li>
<li>
<span class="countryCode">(NZ)</span> <span class="country">New Zealand</span><span class="countrySeparator">: </span><span class="drugName">Elocon | M Mometasone</span>;</li>
<li>
<span class="countryCode">(PE)</span> <span class="country">Peru</span><span class="countrySeparator">: </span><span class="drugName">Dermacortine | Dermosona | Elocom | Flogocort | Flonase | Ladexol | Moflamet | Momate | Mometaderm | Mometaliv | Mometasona Furoato | Mometax | Novasone</span>;</li>
<li>
<span class="countryCode">(PH)</span> <span class="country">Philippines</span><span class="countrySeparator">: </span><span class="drugName">Allerta dermatec | Diametasone | Elica | Elocon | Lomeane | Metson | Mezo | Momate | Momecort | Momegen | Mosone | Ritemed mometasone furoate | United home dermatec</span>;</li>
<li>
<span class="countryCode">(PK)</span> <span class="country">Pakistan</span><span class="countrySeparator">: </span><span class="drugName">Austamo | Biometa | Elocom | Elvicon | Hivate | Malite | Medison | Momate | Momeson | Mometop | Ometo | Santomet | Temoderm | Zametasone</span>;</li>
<li>
<span class="countryCode">(PL)</span> <span class="country">Poland</span><span class="countrySeparator">: </span><span class="drugName">Edelan | Elitasone | Elocom | Elosone | Eztom | Ivoxel | Momarid | Momecutan | Momederm | Ovixan</span>;</li>
<li>
<span class="countryCode">(PR)</span> <span class="country">Puerto Rico</span><span class="countrySeparator">: </span><span class="drugName">Elocon</span>;</li>
<li>
<span class="countryCode">(PT)</span> <span class="country">Portugal</span><span class="countrySeparator">: </span><span class="drugName">Desdek | Elocom | Mometasona Mylan</span>;</li>
<li>
<span class="countryCode">(PY)</span> <span class="country">Paraguay</span><span class="countrySeparator">: </span><span class="drugName">Dermosona | Elocon | Suavicort</span>;</li>
<li>
<span class="countryCode">(QA)</span> <span class="country">Qatar</span><span class="countrySeparator">: </span><span class="drugName">Elica | Elna | Elocom | M-Pad | Mesone | Metaz | Zynovate</span>;</li>
<li>
<span class="countryCode">(RO)</span> <span class="country">Romania</span><span class="countrySeparator">: </span><span class="drugName">Elocom</span>;</li>
<li>
<span class="countryCode">(RU)</span> <span class="country">Russian Federation</span><span class="countrySeparator">: </span><span class="drugName">Avecort | Elocom | Gistan h | Histan n | Momat | Momederm | Mometason akrikhin | Mometasone | Silkaren | Uniderm</span>;</li>
<li>
<span class="countryCode">(SA)</span> <span class="country">Saudi Arabia</span><span class="countrySeparator">: </span><span class="drugName">Alerson | Avocom | Eczaderm | Elica | Elna | Elocom | Locasone | Metaz | Mometamed | Xemaderm | Zynovate</span>;</li>
<li>
<span class="countryCode">(SE)</span> <span class="country">Sweden</span><span class="countrySeparator">: </span><span class="drugName">Demoson | Elocon | Mometason glenmark | Mometasone teva | Ovixan</span>;</li>
<li>
<span class="countryCode">(SG)</span> <span class="country">Singapore</span><span class="countrySeparator">: </span><span class="drugName">Elomet | Elosone | Melomet | Vizomet</span>;</li>
<li>
<span class="countryCode">(SI)</span> <span class="country">Slovenia</span><span class="countrySeparator">: </span><span class="drugName">Cutticom | Elocom | Ovixan</span>;</li>
<li>
<span class="countryCode">(SK)</span> <span class="country">Slovakia</span><span class="countrySeparator">: </span><span class="drugName">Elocom</span>;</li>
<li>
<span class="countryCode">(TH)</span> <span class="country">Thailand</span><span class="countrySeparator">: </span><span class="drugName">Elomet | Momate | Mometasone gpo</span>;</li>
<li>
<span class="countryCode">(TN)</span> <span class="country">Tunisia</span><span class="countrySeparator">: </span><span class="drugName">Mesone</span>;</li>
<li>
<span class="countryCode">(TR)</span> <span class="country">Turkey</span><span class="countrySeparator">: </span><span class="drugName">Codermo | Elocon | K mexader | M-Furo | Momecon</span>;</li>
<li>
<span class="countryCode">(TW)</span> <span class="country">Taiwan</span><span class="countrySeparator">: </span><span class="drugName">Dance | Dermotasone | Elisone | Elofute | Elomet | Eversone | Honmet | Lomeane | Mentasone | Metsone | Mifusin | Minyear | Mofuroate | Molison | Momesone | Monovel | Mosone | Murozo | Pydercon | Shu fu neng</span>;</li>
<li>
<span class="countryCode">(UA)</span> <span class="country">Ukraine</span><span class="countrySeparator">: </span><span class="drugName">Elocom | Eloderm | Moleskin | Momat | Momederm | Mometox</span>;</li>
<li>
<span class="countryCode">(UG)</span> <span class="country">Uganda</span><span class="countrySeparator">: </span><span class="drugName">Elocom | Xemaderm</span>;</li>
<li>
<span class="countryCode">(UY)</span> <span class="country">Uruguay</span><span class="countrySeparator">: </span><span class="drugName">Elocon | Suavicort</span>;</li>
<li>
<span class="countryCode">(VE)</span> <span class="country">Venezuela, Bolivarian Republic of</span><span class="countrySeparator">: </span><span class="drugName">Dermacortine | Elocon | Elomet | Furuoativ | Momate | Momeq | Mometasona | Mometasona Furoato</span>;</li>
<li>
<span class="countryCode">(VN)</span> <span class="country">Viet Nam</span><span class="countrySeparator">: </span><span class="drugName">Sagamome</span>;</li>
<li>
<span class="countryCode">(ZA)</span> <span class="country">South Africa</span><span class="countrySeparator">: </span><span class="drugName">Aspen mometasone | Elica | Elocon | Elomet | Momate | Mometagen</span>;</li>
<li>
<span class="countryCode">(ZM)</span> <span class="country">Zambia</span><span class="countrySeparator">: </span><span class="drugName">Elocom</span></li></ul></div>
</div>
</div>
</div>
</div><div class="headingAnchor" id="references"><ol id="reference">
<li>
<div class="reference" id="lexi-content-ref-9024461">
<a name="9024461"></a>American Academy of Pediatrics Committee on Drugs. "Inactive" ingredients in pharmaceutical products: update (subject review). <i>Pediatrics</i>. 1997;99(2):268-278.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/mometasone-topical-drug-information/abstract-text/9024461/pubmed" id="9024461" target="_blank">9024461</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33950165">
<a name="33950165"></a>Andersson NW, Skov L, Andersen JT. Evaluation of topical corticosteroid use in pregnancy and risk of newborns being small for gestational age and having low birth weight. <i>JAMA Dermatol.</i> 2021;157(7):788-795. doi:10.1001/jamadermatol.2021.1090<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/mometasone-topical-drug-information/abstract-text/33950165/pubmed" id="33950165" target="_blank">33950165</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24528912">
<a name="24528912"></a>Butler DC, Heller MM, Murase JE. Safety of dermatologic medications in pregnancy and lactation: Part II. Lactation. <i>J Am Acad Dermatol</i>. 2014;70(3):417.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/mometasone-topical-drug-information/abstract-text/24528912/pubmed" id="24528912" target="_blank">24528912</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28233354">
<a name="28233354"></a>Chi CC, Kirtschig G, Aberer W, et al. Updated evidence-based (S2e) European Dermatology Forum guideline on topical corticosteroids in pregnancy. <i>J Eur Acad Dermatol Venereol</i>. 2017;31(5):761-773.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/mometasone-topical-drug-information/abstract-text/28233354/pubmed" id="28233354" target="_blank">28233354</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21729030">
<a name="21729030"></a>Chi CC, Kirtschig G, Aberer W, et al. Evidence-based (S3) guideline on topical corticosteroids in pregnancy. <i>Br J Dermatol</i>. 2011;165(5):943-952.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/mometasone-topical-drug-information/abstract-text/21729030/pubmed" id="21729030" target="_blank">21729030</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26497573">
<a name="26497573"></a>Chi CC, Wang SH, Wojnarowska F, Kirtschig G, Davies E, Bennett C. Safety of topical corticosteroids in pregnancy. <i>Cochrane Database Syst Rev</i>. 2015;(10):CD007346. doi:10.1002/14651858.CD007346.pub3<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/mometasone-topical-drug-information/abstract-text/26497573/pubmed" id="26497573" target="_blank">26497573</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32738429">
<a name="32738429"></a>Elmets CA, Korman NJ, Prater EF, et al. Joint AAD-NPF guidelines of care for the management and treatment of psoriasis with topical therapy and alternative medicine modalities for psoriasis severity measures. <i>J Am Acad Dermatol.</i> 2021;84(2):432-470. doi:10.1016/j.jaad.2020.07.087<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/mometasone-topical-drug-information/abstract-text/32738429/pubmed" id="32738429" target="_blank">32738429</a>]</span>
</div>
</li>
<li>
<div class="reference">
                  Elocom (mometasone furoate) [product monograph]. Kirkland, Quebec, Canada: Organon Canada Inc; April 2021.</div>
</li>
<li>
<div class="reference">
                  Elocon cream (mometasone furoate) [prescribing information]. Whitehouse Station, NJ: Merck &amp; Co, Inc; May 2018.</div>
</li>
<li>
<div class="reference">
                  Elocon lotion (mometasone furoate) [prescribing information]. Whitehouse Station, NJ: Merck &amp; Co, Inc; July 2019.</div>
</li>
<li>
<div class="reference">
                  Elocon ointment (mometasone furoate) [prescribing information]. Whitehouse Station, NJ: Merck &amp; Co, Inc; May 2018.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16677965">
<a name="16677965"></a>Leachman SA, Reed BR. The use of dermatologic drugs in pregnancy and lactation. <i>Dermatol Clin</i>. 2006;24(2):167-197, vi.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/mometasone-topical-drug-information/abstract-text/16677965/pubmed" id="16677965" target="_blank">16677965</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32265601">
<a name="32265601"></a>Meyers RS, Thackray J, Matson KL, et al. <i>K</i>ey Potentially <i>I</i>nappropriate <i>D</i>rugs in Pediatrics: The KIDs List. <i>J Pediatr Pharmacol Ther</i>. 2020;25(3):175-191.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/mometasone-topical-drug-information/abstract-text/32265601/pubmed" id="32265601" target="_blank">32265601</a>]</span>
</div>
</li>
<li>
<div class="reference">
                  Mometasone furoate solution [prescribing information]. Melville, NY: E. Fougera &amp; Co; November 2015.</div>
</li>
<li>
<div class="reference">
                  Mometasone furoate solution [prescribing information]. Mahwah, NJ: Glenmark Pharmaceuticals Inc, USA; May 2020.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33108015">
<a name="33108015"></a>Oakley R, Arents BWM, Lawton S, Danby S, Surber C. Topical corticosteroid vehicle composition and implications for clinical practice. <i>Clin Exp Dermatol.</i> 2021;46(2):259-269. doi:10.1111/ced.14473<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/mometasone-topical-drug-information/abstract-text/33108015/pubmed" id="33108015" target="_blank">33108015</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19188870">
<a name="19188870"></a>Shehab N, Lewis CL, Streetman DD, Donn SM. Exposure to the pharmaceutical excipients benzyl alcohol and propylene glycol among critically ill neonates. <i>Pediatr Crit Care Med</i>. 2009;10(2):256-259.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/mometasone-topical-drug-information/abstract-text/19188870/pubmed" id="19188870" target="_blank">19188870</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33719380">
<a name="33719380"></a>Stacey SK, McEleney M. Topical corticosteroids: choice and application. <i>Am Fam Physician.</i> 2021;103(6):337-343.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/mometasone-topical-drug-information/abstract-text/33719380/pubmed" id="33719380" target="_blank">33719380</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20027937">
<a name="20027937"></a>Tadicherla S, Ross K, Shenefelt PD, Fenske NA. Topical corticosteroids in dermatology. <i>J Drugs Dermatol.</i> 2009;8(12):1093-105.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/mometasone-topical-drug-information/abstract-text/20027937/pubmed" id="20027937" target="_blank">20027937</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31231864">
<a name="31231864"></a>Vestergaard C, Wollenberg A, Barbarot S, et al. European task force on atopic dermatitis position paper: treatment of parental atopic dermatitis during preconception, pregnancy and lactation period. <i>J Eur Acad Dermatol Venereol.</i> 2019;33(9):1644-1659. doi:10.1111/jdv.15709<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/mometasone-topical-drug-information/abstract-text/31231864/pubmed" id="31231864" target="_blank">31231864</a>]</span>
</div>
</li>
<li>
<div class="reference">
                  World Health Organization (WHO). Breastfeeding and maternal medication, recommendations for drugs in the eleventh WHO model list of essential drugs. http://www.who.int/maternal_child_adolescent/documents/55732/en/. Published 2002.</div>
</li></ol></div><div id="topicVersionRevision">Topic 9782 Version 305.0</div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
